Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.

Twist Bioscience (NASDAQ:TWST) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, ...

Fiscal 2025 guidance includes projected revenue growth of 17%-20% and a gross margin target of 48%, improving to 50% by Q4FY25. Twist Bioscience shipped products to approximately 3,562 customers in ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Normalization by Ligation™ library preparation technology processes thousands of samples at low cost with enhanced multiplexing and novel streamlined workflow SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

Twist Bioscience Corporation TWST will release earnings results for its fourth quarter, before the opening bell on Monday, Nov. 18. Analysts expect the South San Francisco, California-based bank to ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended ...

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Monday, 2024-11-18. Here's what investors need to know before the announcement. Analysts estimate that Twist ...